West Coast Lunchtime Legal Briefing Teleconference - Patents & the Supreme Court: What Myriad and Monsanto Mean for Life Sciences Technologies

August 21, 2013

Although the recent Myriad and Monsanto decisions purport to be closely tied to their facts, the Court’s reasoning will affect industry players well outside the realms of human genes and genetically modified seeds. Myriad could upset established patenting strategies for technologies as diverse as therapeutic proteins, stem cells, and herbal extracts. Monsanto suggests that patent holders should reconsider contract provisions for replicable technologies like plasmids, genetically modified organisms, and cell lines.